Josh Howell, PharmD, BCOP

Letters to the Editor

Atezolizumab Plus Bevacizumab Is Cost-Effective for Advanced HCC When Utilizing Biosimilars

10/20/2021

Aimee Ginsburg, PharmD, BCPS

Leslie Busby, MD

Kaci Dominguez, PharmD

Josh Howell, PharmD, BCOP

Aimee Ginsburg, PharmD, BCPS, and colleagues argue that atezolizumab plus bevacizumab is cost-effective when compared with sorafenib under current pricing, despite contradicting findings from a study presented at ASCO 2021.

Aimee Ginsburg, PharmD, BCPS,...

10/20/2021

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Josh Howell, PharmD, BCOP

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products